報價延遲最少15分鐘:2024/12/23 22:30 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.03 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.09/-0.82
|
|
企業價值
30.89M
|
| 資產負債 |
|
每股賬面淨值
1.09
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
19.05M
|
|
每股收益
1.73
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/12/23 22:30 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy. |